Effects of an oral enzyme preparation, Chymoral, upon serum proteins associated with injury (acute phase reactants) in man.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001798:Blood Proteins / Q000032:analysis; D002097:C-Reactive Protein / Q000032:analysis; D002918:Chymotrypsin / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006023:Glycoproteins / Q000032:analysis; D059685:Herniorrhaphy; D006801:Humans; D005779:Immunodiffusion; D008259:Macroglobulins / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013997:Time Factors; D014357:Trypsin / Q000008:administration & dosage / Q000627:therapeutic use*; D014361:Trypsin Inhibitors / Q000097:blood; D000515:alpha 1-Antitrypsin / Q000097:blood
D001798:Blood Proteins; D006023:Glycoproteins; D008259:Macroglobulins; D010919:Placebos; D014361:Trypsin Inhibitors; D000515:alpha 1-Antitrypsin; D002097:C-Reactive Protein; D002918:Chymotrypsin; D014357:Trypsin